Gradually tapering off antipsychotics: lessons for practice from case studies and neurobiological principles

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Medicine

Background:

• Increasing focus on deprescribing antipsychotic medications in psychiatry.
• Recognition that not all patients with psychotic disorders require lifelong antipsychotic treatment.

Purpose of the Study:

• To provide instruction on the deprescribing of antipsychotic medication.
• To summarize empirical and theoretical papers on antipsychotic deprescribing.
• To examine case studies related to antipsychotic dose reduction.

Main Methods:

• Review of empirical and theoretical literature on antipsychotic deprescribing.
• Analysis of case studies illustrating antipsychotic dose reduction.
• Examination of recent study findings on tapering rates and relapse.

Main Results:

• Slower antipsychotic tapering (months) is linked to lower relapse rates compared to rapid tapering (weeks).
• Antipsychotic dose reduction can precipitate or worsen psychotic symptoms, with slower reduction potentially minimizing this effect.
• Gradual dose reduction may mitigate disruption to homeostatic equilibria and reduce the risk of psychotic symptom exacerbation.

Conclusions:

• Slower antipsychotic tapering allows for adaptation, potentially reducing relapse risk.
• Exacerbation of psychotic symptoms during reduction may indicate a need for a more gradual taper, not necessarily a higher long-term dose.
• Prudent gradual reduction of antipsychotics, particularly after long-term use, is recommended in clinical practice.